The current financial score of Arcus Biosciences Inc is 7.41. Its financial status is weak, and its operating efficiency is high.
The current valuation score of Arcus Biosciences Inc is 7.09. Its current P/E ratio is -5.63, which is -71.18% below the recent high of -1.62 and -76.86% above the recent low of -9.96.
The current earnings forecast score of Arcus Biosciences Inc is 8.15. The average price target is 41.00, with a high of 50.00 and a low of 23.00.
The current price momentum score of Arcus Biosciences Inc is 5.20. Currently, the stock price is trading between the resistance level at 22.73 and the support level at 15.20, making it suitable for range-bound swing trading.
The current institutional shareholding score of Arcus Biosciences Inc is 7.00. The latest institutional shareholding proportion is 82.11%, representing a quarter-over-quarter increase of 34.03%.
The current risk assessment score of Arcus Biosciences Inc is 5.05. The company's beta value is 0.84. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.